EGFR and cancer: It is known that 1,25(OH)2D3 inhibits the EGFR signaling pathway in cancer cells, and perhaps, PRI-2191 could contribute to a decrease in IL-8 levels by inhibiting this pathway in HCC827 cells [70,71,72].